Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ifm Therapeutics Inc.
Headquarters: Boston, MA, United States of America
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Jan 24, 2025
Finance
Ascentage lists on NASDAQ as Odyssey, Sionna, Aardvark plot IPOs
In BioCentury’s Finance Report, two more companies plan Hong Kong listings; Disc Medicine, Arctic raise cash
BioCentury | May 15, 2024
Management Tracks
Third Harmonic hires Dinsmore as CSO
Plus: Matthew Shields to lead global operations at Teva, and updates from Compugen, Enhanc3D, Geneoscopy and Autism Speaks
BioCentury | Dec 6, 2023
Deals
Dec. 5 Quick Takes: Nearing clinic, Odyssey raises $101M series C
Plus: Genentech PI3K combo meets PFS endpoint in Phase III and more from ImmunoGen, SpringWorks, Eligo, BrainChild, Axcella, Sanofi, Aqemia and IGM
BioCentury | Oct 14, 2022
Finance
Oct. 13 Quick Takes: Epic $168M round for Glick’s Odyssey
Plus Dice raises $300M on back of data, Liu’s Prime Medicine seeking $1.6B valuation, and updates from VectivBio, CSPC, Relmada and more
BioCentury | Dec 7, 2021
Emerging Company Profile
Odyssey: Syndicate led by OrbiMed, SR One infuses Glick newco with $218M
Led by serial entrepreneur Gary Glick, a veteran team with a deep bench is building a pipeline in inflammation and oncology
BioCentury | Feb 20, 2021
Product Development
BMS turns to mechanistic diversity in early oncology pipeline
BMS has holes to fill with upcoming patent expirations
BioCentury | Oct 26, 2020
Emerging Company Profile
Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M
Syndicate that backed IFM invests in experienced precision oncology team
BioCentury | Sep 22, 2020
Deals
Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout
Acquisition tops Bayer’s KaNDy buy as Europe’s largest this year
BioCentury | Jun 4, 2020
Finance
NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B
BioCentury | Dec 2, 2019
Financial News
IFM Therapeutics gets $55.5M to launch incubator and new subsidiaries
Items per page:
1 - 10 of 35